The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Canada
Fluorodeoxyglucose F18
Gallium Radioisotopes
/ therapeutic use
Humans
Ligands
Male
Multicenter Studies as Topic
Observational Studies as Topic
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
Prospective Studies
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Radionuclide Imaging
Radiopharmaceuticals
/ therapeutic use
#PCSM
#ProstateCancer
#uroonc
18F-FDG
68Ga-DOTATATE (Octreotate)
68Ga-PSMA-617
intra-patient inter-metastasis heterogeneity
metastatic castration-resistant prostate cancer
neuroendocrine differentiation
positron emission tomography/computed tomography
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
22
10
2021
medline:
26
8
2022
entrez:
21
10
2021
Statut:
ppublish
Résumé
To determine the prevalence of intra-patient inter-metastatic heterogeneity based on positron emission tomography (PET)/computed tomography (CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and to determine the prevalence of neuroendocrine disease in these patients and their eligibility for radioligand therapies (RLTs). This multicentre observational prospective clinical study will include 100 patients with mCRPC from five Canadian academic centres. Patients with radiological or biochemical progression and harbouring at least three metastases by conventional imaging will be accrued. Intra-patient inter-metastatic heterogeneity will be determined with triple-tracer imaging using fluorine-18 fluorodeoxyglucose ( The proposed triple-tracer approach will allow whole-body mCRPC characterisation, investigating the inter-metastatic heterogeneity in order to better understand the phenotypic plasticity of prostate cancer, including the neuroendocrine transdifferentiation that occurs during mCRPC progression. Based on This study will add novel, biologically relevant dimensions to molecular imaging: the non-invasive detection of inter-metastatic heterogeneity and transdifferentiation to neuroendocrine prostate cancer by using a multi-tracer PET/CT strategy to further personalise the care of patients with mCRPC.
Identifiants
pubmed: 34674367
doi: 10.1111/bju.15621
pmc: PMC9546087
doi:
Substances chimiques
Gallium Radioisotopes
0
Ligands
0
Radiopharmaceuticals
0
copper dotatate CU-64
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
314-322Informations de copyright
© 2021 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Nat Genet. 2015 Jul;47(7):736-45
pubmed: 26005866
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Appl Radiat Isot. 2020 Feb;156:109014
pubmed: 32056692
J Nucl Med. 2002 Jan;43(1):46-55
pubmed: 11801702
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227
pubmed: 28117385
Health Educ Behav. 2010 Jun;37(3):424-51
pubmed: 19797541
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Eur Urol Focus. 2017 Dec;3(6):639-642
pubmed: 28753860
Cent European J Urol. 2017;70(1):37-43
pubmed: 28461986
Eur J Cancer. 2014 Jun;50(9):1610-6
pubmed: 24703897
Clin Nucl Med. 2019 Dec;44(12):978-980
pubmed: 31689280
Int J Urol. 2018 Apr;25(4):345-351
pubmed: 29396873
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Curr Oncol Rep. 2017 May;19(5):32
pubmed: 28361223
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Can Urol Assoc J. 2021 Feb;15(2):E81-E90
pubmed: 33556313
J Nucl Med. 2010 Jun;51(6):875-82
pubmed: 20484441
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Prostate. 2018 Jul;78(10):697-706
pubmed: 29603326
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85
pubmed: 25606573
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Crit Rev Oncol Hematol. 2019 Jun;138:29-37
pubmed: 31092382
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143
pubmed: 33545689
Clin Nucl Med. 2017 Jan;42(1):1-6
pubmed: 27775942
Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205
pubmed: 33678552
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148